Actively Recruiting
Evaluating the Safety and Pharmacokinetics of TQB6426 Injection in Adults with Advanced Solid Tumors
Led by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Updated on 2026-09-15
145
Participants Needed
8
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating TQB6426, an antibody-drug conjugate targeting glypican-3 GPC3, in patients with advanced malignancies. Preclinical studies have shown this drugs potential anti-tumor effects and acceptable safety, leading to this Phase I clinical trial to evaluate its tolerability and pharmacokinetics in humans. The trial has two phases a dose escalation phase where TQB6426 is given by intravenous infusion every three weeks with dose adjustments based on safety, followed by a dose expansion phase using the selected dose from the first phase, also administered every three weeks. Both phases involve careful monitoring of drug effects and adverse events. Participants will undergo regular assessments including laboratory tests, imaging, and biomarker analysis. Researchers will monitor safety outcomes like dose-limiting toxicities and adverse event severity, as well as pharmacokinetic measures such as drug concentration over time. The study may last up to 24 months, with ongoing evaluation of treatment response and survival outcomes.
CONDITIONS
Brief Title
A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors
Research Team
Q
Qiang Xia, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here